

Dr Lal PathLabs Limited records revenue of Rs 798 Cr with a growth of 19.1% in Q1 FY27

New Delhi, India, July 24, 2026 – Dr Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended June 30, 2026.

Consolidated Performance Highlights: Q1 FY27

- Revenue increased by 19.1% in Q1 FY27
- EBITDA for Q1 FY27 increased by 28.7% with a margin of 31.0%
- PAT for Q1 FY27 is Rs 170 Cr. with a margin for of 21.4%
- Interim Dividend of 50% i.e. Rs. 5 per share.
- Cash and Cash equivalents as on 30th June 2026 is Rs. 1,693 Cr.
- Acquisition of 80% equity stake in Sunshine Healthcare Limited, Ghana engaged in diagnostic business for a consideration not exceeding GHS 45.6 million.
- Acquisition of 30% equity stake in Neuome Technologies Private Limited, engaged in innovative solutions in sample preservation and biobanking, for a consideration not exceeding Rs. 3.5 Cr.

Financial Overview (Consolidated) in Rs Cr

Particulars	Q1		
	FY27	FY26	Gr %
Revenue	798	670	19.1%
Material consumed	152	129	
Employee benefit Expenses	133	124	
Fees to collection centres	116	96	
Other Expenses	150	129	
EBITDA	247	192	28.7%
<i>Margins</i>	<i>31.0%</i>	<i>28.7%</i>	
Other Income	32	28	
Depreciation Cost	44	35	
Finance Cost	6	5	
PBT	229	181	26.3%
<i>Margins</i>	<i>28.7%</i>	<i>27.0%</i>	
Income Tax	58	47	
PAT	170	134	27.2%
<i>Margins</i>	<i>21.4%</i>	<i>20.0%</i>	
EPS	10.1	7.9	27.8%

About Dr Lal PathLabs Limited

Dr Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2026 the company has 312 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 7,727 Patient Service Centers (PSCs) and 13,935 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Goel

Group Chief Financial Officer &
CEO- International Business
Dr Lal PathLabs Limited

+91 124 3016500
cfo@lalpathlabs.com

Kritika Khatwani
Adfactors PR

+91 8604801332
kritika.khatwani@adfactorspr.com

For further information on Dr Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.